AHA26: Boehringer’s survodutide establishes CV safety in SYNCHRONIZE-CVOT
On 9 November, at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, Biykem Bozkurt of Baylor College of …
Post
-
-
AHA26: Semaglutide’s real-world CV benefits highlight importance of persistence
This year at the American Heart Association (AHA) Scientific Sessions, findings from a nationwide Norwegian study assessing cardiovascular outcomes among …
-
BIO Europe: Financing, AI and geopolitics shape biotech discourse
In recent years, the European biotechnology sector has been thrust into a period of notable change, with new technologies and …
-
FDA puts commissioner’s priority voucher framework on ice
The US Food and Drug Administration (FDA) appears to have quietly paused the Commissioner’s National Priority Voucher (CNPV) pilot programme, …
-
Neurosterix pockets $105m to advance neuropsychiatry pipeline
Swiss biotech company Neurosterix has banked $105m in a Series B funding round to push its range of neuropsychiatric candidates …
-
BMS sets unified research and development structure for 2027
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective …
-
Takeda begins US distribution of narcolepsy type 1 drug Orzeyful
Japanese pharma major Takeda has commercially launched Orzeyful (oveporexton) in the US for the treatment for adult patients with narcolepsy …
-
Eli Lilly beats Novo to oral China GLP-1RA market on NMPA approval
Eli Lilly has beaten its staunch obesity rival Novo Nordisk to market in China by securing an approval for its …
-
Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund
With an eye on entering the obesity market dominated by Eli Lilly, Pfizer has secured $1.5bn from Blackstone Life Sciences …
-
Beyond GLP-1RA’s: Novel mechanisms and combos to shape future of obesity market
In recent years, the emergence of the incretin drug class has revolutionised the cardiometabolic treatment space, as doctors increasingly prescribe …
-
Podcast: Longevity, China, and AI the talk of the town at BIO Europe 2026
With the curtains closing on another year at BIO-Europe, the attending editorial team is still revelling in the interesting conversations …
-
FDA and EMA waive paediatric studies for Shanton’s gout candidate
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have granted paediatric clinical trial waivers to …
-
Life-extending peptides are likely not around the corner
Excitement in the longevity space over peptides comes with the caveat that many claims about their life-extending potential are incomplete …
-
Litmys and PharmaACE partner on pharma commercial forecasting
Life sciences consulting firms Litmys and PharmaACE have formed a strategic collaboration to provide commercial forecasting and decision-making services to …
-
Building Annex 1 readiness into primary packaging
The revised EU GMP Annex 1 guideline places contamination prevention within a coordinated, risk-based strategy. It identifies containers, closures, supplier …
